Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject

Clinical Therapeutics

Volumn 30, Issue 7, 2008, Pages 1324-1329

  Saraceno, Rosita ^a   Teoli, Miriam ^a   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

chemotherapy side effects; hydroxyurea; imiquimod; melanonychia; squamous cell carcinomas

Indexed keywords

ALLOPURINOL; FOLIC ACID; FUROSEMIDE; HYDROXYUREA; IMIQUIMOD; IRON; SPIRONOLACTONE; THEOPHYLLINE;

ACTINIC KERATOSIS; AGED; ANEMIA; ARTICLE; CASE REPORT; CHRONIC BRONCHITIS; DIFFUSE LONGITUDINAL MELANONYCHIA; GOUT; HUMAN; HYPERPIGMENTATION; KERATOACANTHOMA; LIVER CIRRHOSIS; MALE; MYELOID METAPLASIA; NAIL DISEASE; PERIUNGUAL HYPERPIGMENTATION; REMISSION; SQUAMOUS CELL CARCINOMA;

AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HUMANS; HYDROXYUREA; HYPERPIGMENTATION; MALE; MYELOPROLIFERATIVE DISORDERS; NAIL DISEASES; SKIN NEOPLASMS;

EID: 48549087758     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(08)80057-4     Document Type: Article

References (20)

1. Rice L., and Baker K.R. Current management of the myeloproliferative disorders: A case-based review. Arch Pathol Lab Med 130 (2006) 1151-1156
2. Cervantes F., Mesa R., and Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J. 13 (2007) 377-383
3. Vassallo C., Passamonti F., Merante S., et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol 26 (2001) 141-148
4. Aste N., Fumo G., Contu F., et al. Nail pigmentation caused by hydroxyurea: Report of 9 cases. J Am Acad Dermatol 47 (2002) 146-147
5. Neynaber S., Wolff H., Plewig G., and Wienecke R. Longitudinal melanonychia induced by hydroxyurea therapy [in German]. J Dtsch Dermatol Ges 2 (2004) 588-591
6. Cakir B., Sucak G., and Haznedar R. Longitudinal pigmented nail bands during hydroxyurea therapy. Int J Dermatol 36 (1997) 236-237
7. Hernández-Martín A., Ros-Forteza S., and de Unamuno P. Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea. J Am Acad Dermatol 41 (1999) 333-334
8. Nixon D.W. Alterations in nail pigment with cancer chemotherapy. Arch Intern Med 136 (1976) 1117-1118
9. Piraccini B.M., Iorizzo M., and Tosti A. Drug-induced nail abnormalities. Am J Clin Dermatol 4 (2003) 31-37
10. De Simone C., Guerriero C., Guidi B., et al. Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea. Eur J Dermatol 8 (1998) 114-115
11. Papi M., Didona B., DePità O., et al. Multiple skin tumors on light-exposed areas during long-term treatment with hydroxyurea. J Am Acad Dermatol 28 (1993) 485-486
12. Angeli-Besson C., Koeppel M.C., Jacquet P., et al. Multiple squamous-cell carcinomas of the scalp and chronic myeloid leukemia. Dermatology 191 (1995) 321-322
13. Peris K., Micantonio T., Fargnoli M.C., et al. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol 55 (2006) 324-327
14. Schön M.P., and Schön M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 27 (2008) 190-199
15. Fitzpatrick T.B. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 124 (1988) 869-871
16. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245
17. Aldara® (imiquimod) package insert. Bad Homberg, Germany: MEDA Pharma GmbH & Co. KG; January 2008.
18. Rashid K., Ng R., Mastan A., et al. Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia. Leuk Lymphoma 46 (2005) 1051-1055
19. Mehregan A., and Plotnick H. Pigmented keratoacanthoma. Arch Dermatol 120 (1984) 1417
20. Francis A.A., Blevins R.D., Carrier W.L., et al. Inhibition of DNA repair in ultraviolet-irradiated human cells by hydroxyurea. Biochem Biophys Acta 563 (1979) 385-392